This morning, Array Biopharma will outline its plans to investors to get its first wholly-owned drug, a treatment for the blood cancer multiple myeloma, approved by the Food and Drug Administration.

A difficult 2021 for Array Technologies appears to have given way to a positive 2022 as the company recovers from damaging supply side issues. Image: Array US solar tracker supplier Array Technologies ...

Array Technologies (NASDAQ:ARRY) +2.6% in Wednesday's trading as Janney initiated coverage with a Buy rating and $37 price target, saying investment tax credits "provide a path to significant ...

Although numerous platforms have been developed to support array CGH studies, they all revolve around a common principle of detecting copy number alterations between two samples (Figure 1). These ...

Astrocytic tumours are the most common human primary malignancies of brain. Adult astrocytic tumours are subclassified into three malignancy grades, namely diffuse astrocytomas (malignancy grade II, ...